Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled crossover study Meeting Abstract
| Authors: | Gounder, M. M.; Somaiah, N.; Attia, S.; Chawla, S. P.; Villalobos, V. M.; Chmielowski, B.; Burgess, M. A.; Schwartz, G. K.; Riedel, R. F.; von Mehren, M.; Wagner, A. J.; Choy, E.; Verma, S.; Mudenda, B.; Sadanowicz, M.; Shah, J. J.; Li, L. L.; Shacham, S.; Kauffman, M. G.; Razak, A. R. A. |
| Abstract Title: | Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled crossover study |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 579s |
| Language: | English |
| ACCESSION: | WOS:000442916003595 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.11512 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 11512 -- Source: Wos |
